
Sundance Diagnostics develops advanced genetic safety tests to predict patient risks and improve drug safety.
Founded with the mission to enhance pharmaceutical safety, Sundance Diagnostics focuses on developing genetic safety tests to predict patients' risks of antidepressant-induced suicidal thoughts or behaviors. Utilizing cutting-edge genetic technologies, the company aims to save lives, improve treatment outcomes, and increase overall drug safety. Their primary market includes healthcare providers and pharmaceutical companies seeking to mitigate the severe side effects associated with antidepressant medications.
Sundance Diagnostics has garnered attention from notable figures in the medical and biotech fields and has attracted investment from key stakeholders committed to advancing genetic testing. The company's pioneering work in predictive genetic safety has positioned it as a leader in personalized medicine, contributing significantly to patient safety and the broader healthcare industry. Their innovative approach has the potential to revolutionize how mental health treatments are prescribed, ultimately reducing adverse effects and improving patient care.

Juno Diagnostics

SureGene

Predictive Health Diagnostics Company

GeneDx Holdings
genedx.com

Geneticure
geneticure.com

Specific Diagnostics

Invitae
invitae.com

Fulgent Diagnostics

Genetic Foresight

Geneicd

Myriad Genetics
myriad.com

Empowered Diagnostics

Iverson Genetic Diagnostics

Population Diagnostics

Durin Technologies
Companies similar to Sundance Diagnostics include Juno Diagnostics, SureGene, Predictive Health Diagnostics Company and GeneDx Holdings.
Sundance Diagnostics was founded in 2012.
Sundance Diagnostics' headquarters is located in Grand Junction, CO, US.
Sundance Diagnostics' most recent funding round was for $5.5k (USD) in May 2015.
As of May 19, 2015, Sundance Diagnostics has raised a total of $6.5k (USD).
Sundance Diagnostics has 6 employees as of Feb 5, 2024.